Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have received a consensus rating of “Buy” from the twenty ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $63.00.

A number of equities research analysts have issued reports on DFTX shares. JonesTrading boosted their price target on Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Needham & Company LLC upped their target price on shares of Definium Therapeutics from $50.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $70.00 target price on shares of Definium Therapeutics in a report on Wednesday, August 12th.

Definium Therapeutics Stock Performance

Shares of DFTX opened at $38.23 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. Definium Therapeutics has a one year low of $8.77 and a one year high of $49.70. The firm has a market capitalization of $5.14 billion, a P/E ratio of -11.15 and a beta of 2.23. The business has a fifty day moving average of $43.35 and a 200 day moving average of $29.88.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, sell-side analysts anticipate that Definium Therapeutics will post -3.02 EPS for the current year.

Insider Buying and Selling

In related news, CEO Robert Barrow sold 19,023 shares of Definium Therapeutics stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $37.94, for a total transaction of $721,732.62. Following the transaction, the chief executive officer directly owned 1,494,640 shares in the company, valued at approximately $56,706,641.60. The trade was a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the sale, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This represents a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 67,119 shares of company stock valued at $2,887,496. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new stake in Definium Therapeutics in the 2nd quarter worth approximately $283,999,000. Avoro Capital Advisors LLC bought a new position in shares of Definium Therapeutics during the 4th quarter valued at approximately $66,950,000. Wellington Management Group LLP bought a new position in shares of Definium Therapeutics during the 2nd quarter valued at approximately $138,755,000. Janus Henderson Group PLC grew its holdings in shares of Definium Therapeutics by 8,513.2% in the fourth quarter. Janus Henderson Group PLC now owns 2,411,696 shares of the company’s stock valued at $32,256,000 after purchasing an additional 2,383,696 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Definium Therapeutics in the fourth quarter valued at $17,516,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.